Evaluation of the Effectiveness of Managing Chemotherapy Side Effects Using ePRO and a Standardized Telenursing Program for Cancer Patients
Ulsan University Hospital
414 participants
Jul 9, 2025
INTERVENTIONAL
Conditions
Summary
This is a multicenter randomized controlled clinical trial designed to evaluate the clinical efficacy and cost-effectiveness of a digital health platform that integrates a symptom reporting and management software with a standardized telenursing program, allowing cancer patients to actively monitor, report, and self-manage chemotherapy-related adverse effects.
Eligibility
Inclusion Criteria5
- Adults aged 19 years or older
- Diagnosed with early or advanced gastric, lung, breast, or colon cancer
- Starting first-cycle chemotherapy with a new anticancer agent
- Able to use a smartphone without difficulty
- Willing to provide informed consent to participate in the study
Exclusion Criteria3
- Individuals who have difficulty communicating due to cognitive impairment, visual impairment, hearing impairment, or other reasons
- Individuals who cannot read, write, or understand Korean
- Other individuals deemed inappropriate for participation by the investigators
Interventions
Within Smart Cancer Care Plus, predefined criteria are applied to trigger standardized telenursing interventions. When patients report symptoms of Grade 3 or higher severity, or when a scheduled weekly symptom report is not submitted within 48 hours of the designated reporting date, a structured telephone counseling session is initiated. This process is intended to ensure timely clinical follow-up, support appropriate self-management, and prevent the progression of unmanaged adverse events.
Smart Cancer Care Plus is a digital platform for patient-reported symptom monitoring and management, developed for individuals receiving chemotherapy. The system enables structured reporting of chemotherapy-related adverse events and provides standardized information regarding the severity grading of symptoms, accompanied by evidence-based self-management strategies. This intervention is intended to promote systematic symptom monitoring and to facilitate timely clinical responses to adverse events.
Locations(5)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07405931